As SGLT2 inhibitors dapagliflozin and empagliflozin improved liver enzymes and decreased liver fat [18] we analyzed also SGLT2 protein expression levels in our NAFLD group to elucidate the factors in the development of NASH. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatohepatitis.